This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Investors Remain Skeptical about Bluebird Gene Therapy for Blood Disease

Bluebird Bio is going to have a rough Monday because of the disappointing gene therapy data presented over the weekend at the American Society of Hematology annual meeting.

Global Blood Bolsters Sickle Cell Drug With More Patient Data

Expanded results from a Global Blood study continue to show encouraging reductions in the number of sickled red blood cells, supported by other improvements in measures of the disease.

Bluebird Sickle Cell Gene Therapy Falls Short of High Expectations

Bluebird's challenge is to understand why exemplary results seen in a single French sickle cell patient are not being duplicated in the three other sickle cell patients treated more recently.

Bellicum Therapy Reduces Risk from Mismatched Stem Cell Transplants

Modified donor T cells and a molecular "safety switch" developed by Bellicum Pharmaceuticals improved the safety and outcome of stem cell transplants performed on children suffering from rare blood diseases.

Bluebird, Celgene See Promise in T Cell Therapy for Multiple Myeloma

U.S. researchers using a personalized therapy made from genetically engineered T cells induced remissions in some patients with highly advanced multiple myeloma, a type of blood cancer affecting plasma cells.

Zafgen Obesity Drug Marred by Second Patient Death

Zafgen shares plunge on concerns regulators could step in to halt clinical development of the company's obesity drug for patient-safety reasons.

Biotech Stock Mailbag: Anavex, Northwest Bio, Threshold Therapeutics

TheStreet's biotech columnist Adam Feuerstein answers readers' questions about health care.

BioMarin's Duchenne Drug Is Done, Sarepta Survives but Faces Challenge

I give BioMarin a 5% chance of winning approval for drisapersen from the FDA following a negative advisory panel. I might be too generous.

BioMarin FDA Panel Live Blog
BioMarin FDA Panel Live Blog

11/24/15 - 07:39 AM EST

A panel of outside experts convened by the U.S. Food and Drug Administration will spend all day Tuesday reviewing drisapersen, BioMarin's experimental drug for Duchenne muscular dystrophy (DMD).

Clovis Blowup Conjures Bad Biotech Memories of ImClone Darkness

The last thing the biotech industry needs today is another hit to investor credibility. Clovis isn't helping.

Page 4 of 350
Top Rated Stocks Top Rated Funds Top Rated ETFs